The estimated Net Worth of Christoph H Westphal is at least $14 Milhão dollars as of 8 November 2016. Christoph Westphal owns over 7,000 units of Verastem Inc stock worth over $11,035,130 and over the last 20 years Christoph sold VSTM stock worth over $2,955,832.
Sign up
Christoph Westphal VSTM stock SEC Form 4 insiders trading
Christoph has made over 82 trades of the Verastem Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Christoph sold 3,212,861 units of VSTM stock worth $2,955,832 on 16 October 2018.
The largest trade Christoph's ever made was selling 3,212,861 units of Verastem Inc stock on 16 October 2018 worth over $2,955,832. On average, Christoph trades about 65,191 units every 49 days since 2004. As of 8 November 2016 Christoph still owns at least 3,941,118 units of Verastem Inc stock.
You can see the complete history of Christoph Westphal stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Christoph Westphal's mailing address?
Christoph's mailing address filed with the SEC is C/O VERASTEM, INC.,, 117 KENDRICK STREET, SUITE 500, NEEDHAM, MA, 02494.
Insiders trading at Verastem Inc
Over the last 13 years, insiders at Verastem Inc have traded over $5,883,823 worth of Verastem Inc stock and bought 3,873,819 units worth $28,318,633 . The most active insiders traders include Capital Management, L.P.Ra ..., Christoph H Westphal, eAnsbert Gadicke. On average, Verastem Inc executives and independent directors trade stock every 28 days with the average trade being worth of $112,479. The most recent stock trade was executed by Dan Paterson on 5 August 2024, trading 3,245 units of VSTM stock currently worth $7,009.
What does Verastem Inc do?
verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com
What does Verastem Inc's logo look like?
Complete history of Christoph Westphal stock trades at Alnylam Pharmaceuticals Inc, Momenta Pharmaceuticals, eVerastem Inc
Verastem Inc executives and stock owners
Verastem Inc executives and other stock owners filed with the SEC include:
-
Brian Stuglik,
Chief Executive Officer, Director -
Daniel Paterson,
President, Chief Operating Officer -
Robert Gagnon,
Chief Financial Officer, Chief Business Officer -
Brian M. Stuglik BPHARM, R.Ph., RPh,
CEO & Director -
Brian Stuglik R.Ph., RPh,
CEO & Director -
Daniel W. Paterson,
COO & Pres -
Robert E. Gagnon,
Chief Bus. & Financial Officer -
Michael Kauffman,
Lead Independent Director -
Timothy Barberich,
Independent Director -
Eric Rowinsky,
Independent Director -
Alison Lawton,
Independent Director -
Bruce Wendel,
Independent Director -
Gina Consylman,
Independent Director -
John Doyle,
Investor Relations -
Dr. Michelle Dipp M.D., Ph.D.,
Co-Founder -
Sean C. Flynn,
VP, Gen. Counsel & Sec. -
Erin S. Cox,
Sr. Director of Investor Relations & Corp. Communications -
Dr. Jonathan Pachter Ph.D.,
Chief Scientific Officer -
Dr. Michelle Dipp,
Co-Founder -
Dr. Piyush B. Gupta Ph.D.,
Co-Founder -
Dr. Robert A. Weinberg,
nder & Former Chair of Scientific Advisory Board -
Richard H. Aldrich M.B.A., Mba,
Founder and Consultant -
S. Louise Phanstiel,
Director -
Joseph Chiapponi,
Vice President of Finance -
John B Green,
Chief Financial Officer -
Monica Singh,
General Counsel -
Henri A Termeer,
Director -
Stephen A Sherwin,
Director -
Christoph H Westphal,
Executive Chairman -
Paul A Friedman,
Director -
Karin Anna Tollefson,
Director -
Steven H. Bloom,
Chief Strategy Officer -
Julie B Feder,
Chief Financial Officer -
Robert Forrester,
President and CEO -
Ngoc Diep T. Md, Ph D Le,
Chief Medical Officer -
Joseph M Lobacki,
Executive VP & CCO -
Gregory Berk,
Chief Medical Officer -
Capital Investments L.P.Rid...,
-
Capital Management, L.P.Ra ...,
-
John Johnson,
Director -
Management Co. Llc Deer,
Director -
Iii Lp Chp,
10% owner -
John K Clarke,
Director -
Joanna Horobin,
Chief Medical Officer -
Jonathan Pachter,
VP, Head of Research -
Fund, L.P. Longwood,
10% owner -
Venture Partners Vii L.P.Be...,
-
Stephen Kraus,
Director -
Ansbert Gadicke,
Director -
Bioventures V Llcmpm Bioven...,
-
Piyush Gupta,
10% owner -
Iii Lpchp Iii Management, L...,
-
Daniel Calkins,
Chief Financial Officer -
Frank Neumann,
Chief Medical Officer -
Paul A. Bunn,
Director -
Lesley Kim Solomon,
Director -
Michelle Robertson,
Director -
Anil Kapur,
Director -
Dan Paterson,
President and CEO